Immunofluorescent analysis of HER-2 (green) showing staining in the membrane of SK-BR-3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a HER-2 monoclonal antibody (Product # MA5-13003) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a flourescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Intact SKBR-3 breast cancer cells|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunoprecipitation (IP)||2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13003 targets HER-2 in ICC/IF and IP applications and shows reactivity with Human samples.
The MA5-13003 immunogen is intact SKBR-3 breast cancer cells.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Rapid quantitative profiling of N-glycan by the glycan-labeling method using 3-aminoquinoline/¿-cyano-4-hydroxycinnamic acid.
MA5-13003 was used in immunoprecipitation to develop a rapid and quantitative method for profiling N-glycans
|Kaneshiro K,Watanabe M,Terasawa K,Uchimura H,Fukuyama Y,Iwamoto S,Sato TA,Shimizu K,Tsujimoto G,Tanaka K||Analytical chemistry (84:7146)||2012|
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
MA5-13003 was used in immunoprecipitation to investigate the state of HER1-HER2 interaction and modification in cell lines and tumors
|DeFazio-Eli L,Strommen K,Dao-Pick T,Parry G,Goodman L,Winslow J||Breast cancer research : BCR (13:null)||2011|
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
MA5-13003 was used in ELISA to investigate the inhibitory effect of BIBW2992 on the kinase activity of normal and mutant epidermal growth factor receptor and HER2
|Li D,Ambrogio L,Shimamura T,Kubo S,Takahashi M,Chirieac LR,Padera RF,Shapiro GI,Baum A,Himmelsbach F,Rettig WJ,Meyerson M,Solca F,Greulich H,Wong KK||Oncogene (27:4702)||2008|
Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study.
MA5-13003 was used in ELISA to investigate the alterations of the epidermal growth factor system in patients with benign prostatic hyperplasia
|Tørring N,Møller-Ernst Jensen K,Lund L,Nielsen JE,Djurhuus JC,Poulsen SS,Nexø E||BJU international (89:583)||2002|